Literature DB >> 15201737

Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy.

Andrew J Stephenson1, Michael P Chetner, Keith Rourke, Martin E Gleave, M Signaevsky, Bruce Palmer, James Kuan, Gerald B Brock, Simon Tanguay.   

Abstract

PURPOSE: We characterized relapse patterns in patients with sporadic renal cell carcinoma (RCC) following radical and partial nephrectomy, and developed surveillance guidelines.
MATERIALS AND METHODS: Between 1989 and 2000, 495 patients underwent nephrectomy for RCC at 1 of 5 Canadian referral centers. Median followup was 42 months.
RESULTS: The rate of relapse, time to relapse and site of relapse were associated with pathological stage. Five-year progression-free probability was 93% for pT1, 81% for pT2, 67% for pT3A and 57% for pT3B (p <0.001). Compared to patients with pT1-2 those with pT3A-B lesions had earlier relapse after nephrectomy (median 12 vs 26 months, p = 0.001) and were at higher risk for relapse at abdominal sites (14% vs 1.8%, p < 0.001). Abdominal relapse was detected in the absence of symptoms, abnormal biochemical profile or thoracic metastases detectable by chest x-ray in 7 patients (1.4%) overall, including 3 (0.9%) with pT1, 3 (4%) with pT3A and 1 (3%) with pT3B.
CONCLUSIONS: The risk and the pattern of relapse of RCC after nephrectomy are associated with pathological stage. For the surveillance of recurrent disease after nephrectomy we recommend annual clinical assessment and chest x-ray in pT1-2 cases. Patients with pT3A-B should be followed every 6 months for the first 3 years with clinical assessment and chest x-ray, and annual followup thereafter. The higher risk of abdominal relapse in patients with pT3A-B indicates that they should receive surveillance abdominal imaging. We recommend abdominal computerized tomography 6, 12, 24 and 36 months postoperatively.

Entities:  

Mesh:

Year:  2004        PMID: 15201737     DOI: 10.1097/01.ju.0000132126.85812.7d

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  53 in total

Review 1.  Long-term management of bilateral, multifocal, recurrent renal carcinoma.

Authors:  Gennady Bratslavsky; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

2.  Locally advanced renal cell carcinoma.

Authors:  Mohammed Al Otaibi; Simon Tanguay
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

3.  Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma.

Authors:  Wassim Kassouf; Robert Siemens; Christopher Morash; Louis Lacombe; Michael Jewett; Larry Goldenberg; Joseph Chin; Michael Chetner; Christopher G Wood; Simon Tanguay; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2009-02       Impact factor: 1.862

4.  Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors.

Authors:  Pascal Mouracade; Onder Kara; Julien Dagenais; M J Maurice; R J Nelson; Ercan Malkoc; J H Kaouk
Journal:  World J Urol       Date:  2017-02-14       Impact factor: 4.226

5.  Renal cell carcinoma metastasis to the ciliary body responds to proton beam radiotherapy: a case report.

Authors:  Tarek Alasil; Bahram Khazai; Lilia Loredo; Michael E Rauser
Journal:  J Med Case Rep       Date:  2011-08-03

6.  Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patients.

Authors:  Y A M Kuijpers; R P Meijer; G N Jonges; J de Jong; J L H R Bosch; S Horenblas; A Bex
Journal:  World J Urol       Date:  2016-04-07       Impact factor: 4.226

7.  Analysis of lymph node dissection in patients with ≥7-cm renal tumors.

Authors:  Michael A Feuerstein; Matthew Kent; Wassim M Bazzi; Melanie Bernstein; Paul Russo
Journal:  World J Urol       Date:  2014-01-09       Impact factor: 4.226

8.  The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma.

Authors:  A Ari Hakimi; Ling Chen; Philip H Kim; Daniel Sjoberg; Leonard Glickman; Marc R Walker; Paul Russo
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

9.  Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.

Authors:  Won K Han; Anwar Alinani; Chin-Lee Wu; Dror Michaelson; Massimo Loda; Francis J McGovern; Ravi Thadhani; Joseph V Bonventre
Journal:  J Am Soc Nephrol       Date:  2005-03-02       Impact factor: 10.121

Review 10.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.